People have become increasingly resistant to the use of antibiotics, the world’s most powerful weapon in this medical war, for almost half a century, losing the battle against bacteria. The BBC states that around 1.1 million people die
annually from infections, and the death toll is expected to increase to more than 8 million by 2050 unless immediate action is taken. Whenever we think of the medical field, we think of doctors, nurses, therapists, surgeons, medical technicians, and others. Now, in 2026, Artificial Intelligence has become a potentially life-saving technology that could impact lives worldwide. From creating images to discovering medicines once thought incurable, technology has advanced exponentially.
Thousands of diseases remain incurable, and AI technology, such as TxGNN, is the first of its kind to identify drug candidates for rare diseases and/or conditions without treatments. This AI model has already identified drug candidates for more than 17,000 diseases, and many without any treatments; this represents the largest number of diseases that any single AI model can handle. This work has now been declared free for public use, and the researchers aim to encourage clinician-scientist collaboration, especially for conditions with no or limited treatment options.
“With this tool, we aim to identify new therapies across the disease spectrum, but when it comes to rare, ultrarare, and neglected conditions, we foresee this model could help close, or at least narrow, a gap that creates serious health disparities,” said lead researcher Marinka Zitnik, assistant professor of biomedical informatics in the Blavatnik Institute at HMS. “This is precisely where we see the promise of AI in reducing the global disease burden, in finding new uses for existing drugs, which is also a faster and more cost effective way to develop therapies than designing new drugs from scratch,” the lead researcher added, who’s also an associate faculty member at the Kempner Institute for the Study of Natural and Artificial Intelligence at Harvard University. The tool, the source informs us, has two main goals. One of the goals is to identify treatment candidates with possible side effects, while the other explains the rationale for the decision.
Another example that would benefit individuals with rare conditions and diseases would be the World Economic Forum. AI is reshaping the way drugs are being discovered: identifying disease targets, generating compounds, and predicting safety. The World Economic Forum is partnering with Biopharma to “herd” cells. The World Economic Forum utilizes AI to mine vast amounts of scientific literature, human genetics data, and results from millions of single-cell experiments.
While those three steps seem easy, they are the key to a more rigorous journey ahead, one that unfolds through trial and error. Even though human biology is complex, AI has been paving the way to make that journey easier to navigate more intelligently. AI is expected to accelerate discovery, patient recruitment, and regulatory documentation.
It seems that AI plays a more fundamental role than just ChatGPT and Google Gemini. Based on the data analyzed, the most fundamental question remains: Will AI replace doctors? Well… no, they will not. Artificial Intelligence will pave the way for the discovery of new medicines for diseases once thought incurable.
